title: The role of alpha(v)beta3 integrins in vascular healing.
abstract: Alpha(v)beta3 integrins play an important role in vascular healing. Vascular injury is a stimulus for expression of alpha(v)beta3 by vascular cells and, among other effects, alpha(v)beta3 integrins function in the adhesion of activated platelets to endothelium. white cell/endothelium interactions, platelet-mediated thrombin generation, fibrin clot retraction by nucleated cells, smooth muscle cell (SMC) migration and proliferation, vascular cell apoptosis, and vascular remodeling. There are ten different animal models in which treatment with alpha(v)beta3 antagonists reduced the vascular response, including (neo)intima formation, after mechanical injury. These studies, along with mechanistic data derived from cell culture studies, provide compelling evidence that alpha(v)beta3 integrins are involved in vascular repair processes. The challenge is to develop a therapeutic agent that will prove effective in reducing restenosis in humans following percutaneous coronary intervention (PCI).
authors.affiliation: Thrombosis Research Section, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Mansoor
authors.initials: M
authors.lastname: Sajid
authors.forename: George A
authors.initials: GA
authors.lastname: Stouffer
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000503:physiopathology* / Q000517:prevention & control; D023921:Coronary Stenosis / Q000628:therapy; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000293:injuries / Q000502:physiology*; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology / Q000627:therapeutic use; D023421:Models, Animal; D010215:Papio; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D010973:Platelet Adhesiveness / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects; D013552:Swine; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014657:Vasculitis / Q000188:drug therapy / Q000209:etiology; D014945:Wound Healing / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D019030:Receptors, Vitronectin; C112567:etaracizumab; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab